Trevi Therapeutics Inc
TRVI12.100USD
+0.430+3.68%
收盘 11/11, 16:00（美东）报价延迟15分钟
1.47B总市值
亏损市盈率 TTM
关于 Trevi Therapeutics Inc 公司
Trevi Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发和商业化试验性疗法 Haduvio（纳布啡 ER），用于治疗患有特发性肺纤维化 (IPF) 和其他慢性咳嗽适应症的成人慢性咳嗽，以及治疗结节性痒疹。Haduvio 是纳布啡的口服缓释 (ER) 制剂。纳布啡是一种混合的 k-阿片受体激动剂和 mu-阿片受体拮抗剂。该公司正在对患有与结节性痒疹相关的严重瘙痒症的患者进行 Hadguvio 的 IIb/III 期临床试验。该公司还对 IPF 患者的慢性咳嗽进行了 Haduvio 的 II 期临床试验，该试验称为 II 期 CANAL 试验。该公司的 Haduvio 开发计划包括 IPF 慢性咳嗽计划、RCC 计划和结节性痒疹计划。该公司的子公司是 Trevi Therapeutics Limited。
Trevi Therapeutics Inc简介
公司代码TRVI
公司名称Trevi Therapeutics Inc
上市日期May 07, 2019
CEOMs. Jennifer L. Good
员工数量26
证券类型Ordinary Share
年结日May 07
公司地址195 Church St Fl 14
城市NEW HAVEN
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编06510-2009
电话12033042499
网址https://www.trevitherapeutics.com/
公司代码TRVI
上市日期May 07, 2019
CEOMs. Jennifer L. Good
Trevi Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+68.46%
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
25.98K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Jonathan Carlson
Jonathan Carlson
IR Contact Officer
IR Contact Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+68.46%
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
25.98K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
New Enterprise Associates (NEA)
9.34%
Frazier Life Sciences Management, L.P.
8.42%
Rubric Capital Management LP
7.01%
The Vanguard Group, Inc.
4.77%
BlackRock Institutional Trust Company, N.A.
4.64%
其他
65.82%
持股股东
持股股东
占比
New Enterprise Associates (NEA)
9.34%
Frazier Life Sciences Management, L.P.
8.42%
Rubric Capital Management LP
7.01%
The Vanguard Group, Inc.
4.77%
BlackRock Institutional Trust Company, N.A.
4.64%
其他
65.82%
股东类型
持股股东
占比
Hedge Fund
25.75%
Investment Advisor
23.38%
Investment Advisor/Hedge Fund
17.39%
Venture Capital
14.71%
Private Equity
11.14%
Research Firm
2.32%
Individual Investor
0.80%
Pension Fund
0.35%
Bank and Trust
0.12%
其他
4.03%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
272
116.14M
95.37%
+14.43M
2025Q2
232
94.28M
77.42%
+5.93M
2025Q1
226
89.66M
76.74%
+2.50M
2024Q4
177
80.67M
91.74%
+11.34M
2024Q3
156
59.14M
78.18%
-6.31M
2024Q2
148
56.93M
80.80%
-4.85M
2024Q1
147
52.57M
76.38%
-8.69M
2023Q4
131
54.54M
85.48%
-544.63K
2023Q3
124
54.64M
88.55%
-1.52M
2023Q2
115
54.75M
93.54%
+3.66M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
New Enterprise Associates (NEA)
11.37M
9.34%
-1.85M
-14.01%
Aug 11, 2025
Frazier Life Sciences Management, L.P.
10.26M
8.42%
--
--
Jun 30, 2025
Rubric Capital Management LP
8.53M
7.01%
+3.99M
+87.99%
Jun 30, 2025
The Vanguard Group, Inc.
5.32M
4.37%
+1.48M
+38.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.65M
4.64%
+1.10M
+24.11%
Jun 30, 2025
Vivo Capital, LLC
4.49M
3.69%
+1.00M
+28.67%
Jun 30, 2025
AllianceBernstein L.P.
4.28M
3.52%
+4.26M
+19064.53%
Jun 30, 2025
Woodline Partners LP
4.05M
3.32%
+1.99M
+96.64%
Jun 30, 2025
Invus Public Equities Advisors, LLC
3.94M
3.23%
+1.07M
+37.54%
Jun 30, 2025
Octagon Capital Advisors LP
3.67M
3.02%
+350.00K
+10.54%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
SPDR S&P Pharmaceuticals ETF
1.38%
Invesco Dorsey Wright Healthcare Momentum ETF
1.1%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.03%
ALPS Medical Breakthroughs ETF
0.66%
Invesco Dorsey Wright SmallCap Momentum ETF
0.42%
Optimize Strategy Index ETF
0.29%
Vanguard US Momentum Factor ETF
0.21%
iShares Micro-Cap ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.11%
查看更多
SPDR S&P Pharmaceuticals ETF
占比1.38%
Invesco Dorsey Wright Healthcare Momentum ETF
占比1.1%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.03%
ALPS Medical Breakthroughs ETF
占比0.66%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.42%
Optimize Strategy Index ETF
占比0.29%
Vanguard US Momentum Factor ETF
占比0.21%
iShares Micro-Cap ETF
占比0.15%
ProShares Ultra Nasdaq Biotechnology
占比0.12%
Invesco Nasdaq Biotechnology ETF
占比0.11%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
